Skip to content

Effect of licorice on management of migraine.

Evaluation of licorice clinical effects on diziness resulting from propranolol in patients wih migraine.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014092219253N1
Enrollment
40
Registered
2014-10-23
Start date
2014-11-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine headache. Migraine, unspecified

Interventions

Intervention 1: in cases each green capsule contains350±5miligeram extract of licorice ,it is equal with 1400±20miligeram of powder of root of licorice, that will be taken 2capsule 3times a day(at
Treatment - Drugs
Placebo
in cases each green capsule contains350±5miligeram extract of licorice ,it is equal with 1400±20miligeram of powder of root of licorice, that will be taken 2capsule 3times a day(at morning,noon,nig
In controls each green capsule contains 350±5miligeram starch,that will be taken 2capsules of starch 3times a day(at morning,noon,night) with a glass of water .as totally daily dosage will be 2

Sponsors

Shiraz University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:40 patients with migraine (age18to80y/o)with systolic blood pressure lower than 120mmhg,for prophylactic management of migraine with propranolol are enrolled. Exclusion criteria: patients with hypertension or related remedies, liver, renal, adrenal,diabetic diseases, as well as pregnant participants and those sensitive to licorice are excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Frequency of headache. Timepoint: before and 3months after intervention. Method of measurement: counting.;Frequency of dizziness. Timepoint: before and 3months after intervention. Method of measurement: counting.;Prevalence of dizziness. Timepoint: before and 3months after intervention. Method of measurement: report of patient.;Severity of dizziness. Timepoint: before and 3months after intervention. Method of measurement: numeric scale in 5level.;Systolic blood pressure. Timepoint: before and 3months after intervention. Method of measurement: mmhg with mercurial manometer.;Diastolic blood pressure. Timepoint: before and 3months after intervention. Method of measurement: mmhg with mercurial manometer.;Orthostatic hypotension. Timepoint: before and 3months after intervention. Method of measurement: with mercurial manometer in sleeping ans standing up position after 2minutes.;Severity of headache. Timepoint: before and 3months after intervention. Method of measurement: pain scale0-10.;Severity of headache. Timepoint: before and 3months after intervention. Method of measurement: migraine disability assesment score test.

Secondary

MeasureTime frame
Serum potassium. Timepoint: 6weaks after intervension. Method of measurement: sampling from patients serum,meq per liter.;Weight. Timepoint: before and3months after intervension. Method of measurement: Kg with Digital weighing- machine.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Bahrami

Shiraz University of Medical Science

zizi_b68@yahoo.combahrami.zahra1368@gmail.com+98 71 3843 0456

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026